SidaSubSaharaV1, Main, Exploration, bibRecord, 002E59

Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012

Identifieur interne : 002E59 ( Main/Exploration ); précédent : 002E58; suivant : 002E60

Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012

Auteurs : Kwok Hiu Chang [Hong Kong] ; Wing-Wai Yew [République populaire de Chine]

Source :

Respirology [ 1323-7799 ] ; 2013-01.

RBID : ISTEX:E46F0D353E6ED389C752C58AC7C6945D8785B127

Descripteurs français

Wicri :
- topic : Soins de santé, Soins palliatifs, Santé publique.

English descriptors

Abstract

Multidrug‐resistant (MDR) tuberculosis (TB) denotes bacillary resistance to at least isoniazid and rifampicin. Extensively drug‐resistant (XDR) TB is MDR‐TB with additional bacillary resistance to any fluoroquinolone and at least one second‐line injectable drugs. Rooted in inadequate TB treatment and compounded by a vicious circle of diagnostic delay and improper treatment, MDR‐TB/XDR‐TB has become a global epidemic that is fuelled by poverty, human immunodeficiency virus (HIV) and neglect of airborne infection control. The majority of MDR‐TB cases in some settings with high prevalence of MDR‐TB are due to transmission of drug‐resistant bacillary strains to previously untreated patients. Global efforts in controlling MDR‐TB/XDR‐TB can no longer focus solely on high‐risk patients. It is difficult and costly to treat MDR‐TB/XDR‐TB. Without timely implementation of preventive and management strategies, difficult MDR‐TB/XDR‐TB can cripple global TB control efforts. Preventive strategies include prompt diagnosis with adequate TB treatment using the directly observed therapy, short‐course (DOTS) strategy and drug‐resistance programmes, airborne infection control, preventive treatment of TB/HIV, and optimal use of antiretroviral therapy. Management strategies for established cases of difficult MDR‐TB/XDR‐TB rely on harnessing existing drugs (notably newer generation fluoroquinolones, high‐dose isoniazid, linezolid and pyrazinamide with in vitro activity) in the best combinations and dosing schedules, together with adjunctive surgery in carefully selected cases. Immunotherapy may also have a role in the future. New diagnostics, drugs and vaccines are required to meet the challenge, but science alone is insufficient. Difficult MDR‐TB/XDR‐TB cannot be tackled without achieving high cure rates with quality DOTS and beyond, and concurrently addressing poverty and HIV.

Url:

https://api.istex.fr/document/E46F0D353E6ED389C752C58AC7C6945D8785B127/fulltext/pdf

DOI: 10.1111/j.1440-1843.2012.02257.x

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 004A43
to stream Istex, to step Curation: 004A43
to stream Istex, to step Checkpoint: 000258
to stream Main, to step Merge: 002E72
to stream Main, to step Curation: 002E59

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012</title>
<author><name sortKey="Chang, Kwok Hiu" sort="Chang, Kwok Hiu" uniqKey="Chang K" first="Kwok Hiu" last="Chang">Kwok Hiu Chang</name>
</author>
<author><name sortKey="Yew, Wing Ai" sort="Yew, Wing Ai" uniqKey="Yew W" first="Wing-Wai" last="Yew">Wing-Wai Yew</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E46F0D353E6ED389C752C58AC7C6945D8785B127</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1111/j.1440-1843.2012.02257.x</idno>
<idno type="url">https://api.istex.fr/document/E46F0D353E6ED389C752C58AC7C6945D8785B127/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004A43</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004A43</idno>
<idno type="wicri:Area/Istex/Curation">004A43</idno>
<idno type="wicri:Area/Istex/Checkpoint">000258</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000258</idno>
<idno type="wicri:doubleKey">1323-7799:2013:Chang K:management:of:difficult</idno>
<idno type="wicri:Area/Main/Merge">002E72</idno>
<idno type="wicri:Area/Main/Curation">002E59</idno>
<idno type="wicri:Area/Main/Exploration">002E59</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012</title>
<author><name sortKey="Chang, Kwok Hiu" sort="Chang, Kwok Hiu" uniqKey="Chang K" first="Kwok Hiu" last="Chang">Kwok Hiu Chang</name>
<affiliation></affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Hong Kong</country>
</affiliation>
</author>
<author><name sortKey="Yew, Wing Ai" sort="Yew, Wing Ai" uniqKey="Yew W" first="Wing-Wai" last="Yew">Wing-Wai Yew</name>
<affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Microbiology, the Chinese University of Hong Kong, Hong Kong</wicri:regionArea>
<orgName type="university">Université chinoise de Hong Kong</orgName>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Respirology</title>
<title level="j" type="alt">RESPIROLOGY</title>
<idno type="ISSN">1323-7799</idno>
<idno type="eISSN">1440-1843</idno>
<imprint><biblScope unit="vol">18</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="8">8</biblScope>
<biblScope unit="page" to="21">21</biblScope>
<biblScope unit="page-count">14</biblScope>
<publisher>Blackwell Publishing Asia</publisher>
<pubPlace>Melbourne, Australia</pubPlace>
<date type="published" when="2013-01">2013-01</date>
</imprint>
<idno type="ISSN">1323-7799</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1323-7799</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjunctive</term>
<term>Adjunctive surgery</term>
<term>Agents chemother</term>
<term>Airborne infection control</term>
<term>Antimicrob</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Asian society</term>
<term>Assay</term>
<term>Authors respirology</term>
<term>Bacillary</term>
<term>Bacillary resistance</term>
<term>Chang</term>
<term>Chemother</term>
<term>Chemotherapy</term>
<term>Chest service</term>
<term>Clin</term>
<term>Cohort</term>
<term>Crit</term>
<term>Cure rate</term>
<term>Diagnostic delay</term>
<term>Dosing</term>
<term>Drug resistance</term>
<term>Drug susceptibility</term>
<term>Drugresistant</term>
<term>Drugresistant tuberculosis</term>
<term>Early bactericidal activity</term>
<term>Engl</term>
<term>Food incentives</term>
<term>Global</term>
<term>Global epidemic</term>
<term>Guideline</term>
<term>Health care</term>
<term>High cure rates</term>
<term>High prevalence</term>
<term>Hong kong</term>
<term>Household contacts</term>
<term>Human virus</term>
<term>Immunotherapy</term>
<term>Infection control</term>
<term>Injectable</term>
<term>Injectable agents</term>
<term>Injectable drugs</term>
<term>Isoniazid</term>
<term>Lancet</term>
<term>Leung</term>
<term>Line probe assay</term>
<term>Linezolid</term>
<term>Liquid medium</term>
<term>Management strategies</term>
<term>Mathematical model</term>
<term>Microscopic observation</term>
<term>Molecular assays</term>
<term>Multidrugresistant</term>
<term>Multidrugresistant tuberculosis</term>
<term>Murine model</term>
<term>Mycobacterium</term>
<term>Mycobacterium tuberculosis</term>
<term>Newer generation</term>
<term>Nitrate reductase assay</term>
<term>Palliative care</term>
<term>Plo</term>
<term>Policy statement</term>
<term>Preventive strategies</term>
<term>Preventive treatment</term>
<term>Private practitioners</term>
<term>Programmatic management</term>
<term>Programme</term>
<term>Public health</term>
<term>Pulmonary resection</term>
<term>Pulmonary tuberculosis</term>
<term>Pyrazinamide</term>
<term>Pyrazinamide resistance</term>
<term>Randomized</term>
<term>Rapid culture</term>
<term>Regimen</term>
<term>Resection</term>
<term>Resistant tuberculosis</term>
<term>Respir</term>
<term>Respirology</term>
<term>Retrospective</term>
<term>Retrospective cohort study</term>
<term>Retrospective study</term>
<term>Rifampicin</term>
<term>Sputum</term>
<term>Surg</term>
<term>Susceptibility</term>
<term>Systematic review</term>
<term>Thorac</term>
<term>Treatment adherence</term>
<term>Treatment outcomes</term>
<term>Treatment success</term>
<term>Tuberc</term>
<term>Tuberculosis</term>
<term>Tuberculosis care</term>
<term>Tuberculosis control</term>
<term>Tuberculosis patients</term>
<term>Tuberculosis treatment</term>
<term>Uoroquinolone</term>
<term>Uoroquinolones</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adjunctive</term>
<term>Adjunctive surgery</term>
<term>Agents chemother</term>
<term>Airborne infection control</term>
<term>Antimicrob</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Asian society</term>
<term>Assay</term>
<term>Authors respirology</term>
<term>Bacillary</term>
<term>Bacillary resistance</term>
<term>Chang</term>
<term>Chemother</term>
<term>Chemotherapy</term>
<term>Chest service</term>
<term>Clin</term>
<term>Cohort</term>
<term>Crit</term>
<term>Cure rate</term>
<term>Diagnostic delay</term>
<term>Dosing</term>
<term>Drug resistance</term>
<term>Drug susceptibility</term>
<term>Drugresistant</term>
<term>Drugresistant tuberculosis</term>
<term>Early bactericidal activity</term>
<term>Engl</term>
<term>Food incentives</term>
<term>Global</term>
<term>Global epidemic</term>
<term>Guideline</term>
<term>Health care</term>
<term>High cure rates</term>
<term>High prevalence</term>
<term>Hong kong</term>
<term>Household contacts</term>
<term>Human virus</term>
<term>Immunotherapy</term>
<term>Infection control</term>
<term>Injectable</term>
<term>Injectable agents</term>
<term>Injectable drugs</term>
<term>Isoniazid</term>
<term>Lancet</term>
<term>Leung</term>
<term>Line probe assay</term>
<term>Linezolid</term>
<term>Liquid medium</term>
<term>Management strategies</term>
<term>Mathematical model</term>
<term>Microscopic observation</term>
<term>Molecular assays</term>
<term>Multidrugresistant</term>
<term>Multidrugresistant tuberculosis</term>
<term>Murine model</term>
<term>Mycobacterium</term>
<term>Mycobacterium tuberculosis</term>
<term>Newer generation</term>
<term>Nitrate reductase assay</term>
<term>Palliative care</term>
<term>Plo</term>
<term>Policy statement</term>
<term>Preventive strategies</term>
<term>Preventive treatment</term>
<term>Private practitioners</term>
<term>Programmatic management</term>
<term>Programme</term>
<term>Public health</term>
<term>Pulmonary resection</term>
<term>Pulmonary tuberculosis</term>
<term>Pyrazinamide</term>
<term>Pyrazinamide resistance</term>
<term>Randomized</term>
<term>Rapid culture</term>
<term>Regimen</term>
<term>Resection</term>
<term>Resistant tuberculosis</term>
<term>Respir</term>
<term>Respirology</term>
<term>Retrospective</term>
<term>Retrospective cohort study</term>
<term>Retrospective study</term>
<term>Rifampicin</term>
<term>Sputum</term>
<term>Surg</term>
<term>Susceptibility</term>
<term>Systematic review</term>
<term>Thorac</term>
<term>Treatment adherence</term>
<term>Treatment outcomes</term>
<term>Treatment success</term>
<term>Tuberc</term>
<term>Tuberculosis</term>
<term>Tuberculosis care</term>
<term>Tuberculosis control</term>
<term>Tuberculosis patients</term>
<term>Tuberculosis treatment</term>
<term>Uoroquinolone</term>
<term>Uoroquinolones</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Soins de santé</term>
<term>Soins palliatifs</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Multidrug‐resistant (MDR) tuberculosis (TB) denotes bacillary resistance to at least isoniazid and rifampicin. Extensively drug‐resistant (XDR) TB is MDR‐TB with additional bacillary resistance to any fluoroquinolone and at least one second‐line injectable drugs. Rooted in inadequate TB treatment and compounded by a vicious circle of diagnostic delay and improper treatment, MDR‐TB/XDR‐TB has become a global epidemic that is fuelled by poverty, human immunodeficiency virus (HIV) and neglect of airborne infection control. The majority of MDR‐TB cases in some settings with high prevalence of MDR‐TB are due to transmission of drug‐resistant bacillary strains to previously untreated patients. Global efforts in controlling MDR‐TB/XDR‐TB can no longer focus solely on high‐risk patients. It is difficult and costly to treat MDR‐TB/XDR‐TB. Without timely implementation of preventive and management strategies, difficult MDR‐TB/XDR‐TB can cripple global TB control efforts. Preventive strategies include prompt diagnosis with adequate TB treatment using the directly observed therapy, short‐course (DOTS) strategy and drug‐resistance programmes, airborne infection control, preventive treatment of TB/HIV, and optimal use of antiretroviral therapy. Management strategies for established cases of difficult MDR‐TB/XDR‐TB rely on harnessing existing drugs (notably newer generation fluoroquinolones, high‐dose isoniazid, linezolid and pyrazinamide with in vitro activity) in the best combinations and dosing schedules, together with adjunctive surgery in carefully selected cases. Immunotherapy may also have a role in the future. New diagnostics, drugs and vaccines are required to meet the challenge, but science alone is insufficient. Difficult MDR‐TB/XDR‐TB cannot be tackled without achieving high cure rates with quality DOTS and beyond, and concurrently addressing poverty and HIV.</div>
</front>
</TEI>
<affiliations><list><country><li>Hong Kong</li>
<li>République populaire de Chine</li>
</country>
<settlement><li>Sha Tin</li>
</settlement>
<orgName><li>Université chinoise de Hong Kong</li>
</orgName>
</list>
<tree><country name="Hong Kong"><noRegion><name sortKey="Chang, Kwok Hiu" sort="Chang, Kwok Hiu" uniqKey="Chang K" first="Kwok Hiu" last="Chang">Kwok Hiu Chang</name>
</noRegion>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Yew, Wing Ai" sort="Yew, Wing Ai" uniqKey="Yew W" first="Wing-Wai" last="Yew">Wing-Wai Yew</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E59 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E59 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E46F0D353E6ED389C752C58AC7C6945D8785B127
   |texte=   Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012
}}

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024

	Le SIDA en Afrique subsaharienne (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA en Afrique subsaharienne (serveur d'exploration)

Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012

Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri